NCT02682667

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Recruiting now Last updated 14 April 2026

What this trial tests

trial in Multiple Myeloma in 500 participants. Currently enrolling.

Timeline

11 April 2016

Primary endpoint
1 December 2030

1 December 2032

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	500
Start date	11 April 2016
Primary completion	1 December 2030
Estimated completion	1 December 2032
Sites	1 location across United States

Conditions studied

• Multiple Myeloma — all drugs for Multiple Myeloma →
• Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →
• Leukemia-Lymphoma, Adult T-Cell — all drugs for Leukemia-Lymphoma, Adult T-Cell →
• Hodgkin Disease — all drugs for Hodgkin Disease →

Sponsor

National Cancer Institute (NCI)

Who can join

Adults 18 to 120, any sex, with Multiple Myeloma or Lymphoma, Non-Hodgkin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:

Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments.

Objective:

To better understand the biology of malignancies and why certain cancers respond differently to treatment.

Eligibility:

Adults at least 18 years old with cancer or a pre-cancerous condition.

Design:

Participants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology.

Participants will send tissue blocks or slides from their original tumor biopsy.

At least once, participants will have a medical history, physical exam, and blood and urine tests.

Participants may have the following tests. They may have them more than once:

Apheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm.

Bone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle.

Piece of cancer tissue taken by a needle and syringe.

Computed tomography (CT) scan, magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures.

A small piece of skin removed.

Participants will be contacted by phone once a year to find out how they are doing.

...

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
   Warner BM, Baer AN, Lipson EJ, Allen C, et al · · 2019 · cited 125× · PMID 30996010 · DOI 10.1634/theoncologist.2018-0823